One-year follow-up study after patients with severe COVID-19 received human umbilical cord mesenchymal stem cells treatment.

Lei ShiYou ZhengZhi ChengNingfei JiChangming NiuYan WangTingrong HuangRuyou LiMao HuangXiaolin ChenLei ShuMingjing WuKaili DengJing WeiXueli WangYang CaoJiaxin YanGanzhu Feng

Published in: Stem cell research & therapy (2022)

Chinese Clinical Trial Registration; ChiCTR2000031494; Registered 02 April 2020-Retrospectively registered, http://www.medresman.org.

Keyphrases

umbilical cord
mesenchymal stem cells
clinical trial
coronavirus disease
endothelial cells
sars cov
bone marrow
cell therapy
induced pluripotent stem cells
open label
study protocol
randomized controlled trial
phase ii
stem cells
drug induced